PhRMA hails impact of Medicare Modernization Act

8 March 2019

In a blog post, US industry lobbyist the Pharmaceutical Research and Manufacturers of America (PhRMA) has drawn attention to a recent analysis which compares the impact of the switch from Average Wholesale Price (AWP) for Medicare Part B medicines to the Average Sales Price (ASP) system.

The change was brought in by the Medicare Modernization Act of 2003, which also implemented changes to Part B to make it more market based.

As a result of the policy change, The Moran Company concludes the government and seniors saved a total of $132 billion between 2005 and 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK